Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Brainstorm Cell Therapeutics, Inc shares valued at $6,292 were purchased by Lebovits Chaim on Oct 01 ’24. At $3.43 per share, Lebovits Chaim acquired 1,836 shares. The insider’s holdings grew to 80,960 shares worth approximately $0.14 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Lebovits Chaim purchased 22,000 shares, netting a total of over 5,016 in proceeds. Following the buying of shares at $0.23 each, the insider now holds 1,186,865 shares.
Before that, Dagher Ibrahim B. had sold 63,000 shares from its account. In a trade valued at $22,069, the Chief Medical Officer traded Brainstorm Cell Therapeutics, Inc shares for $0.35 each. Upon closing the transaction, the insider’s holdings decreased to 63,000 shares, worth approximately $0.0.
As published in a research note from Maxim Group on February 04, 2021, Brainstorm Cell Therapeutics, Inc [BCLI] has been rated up from a Hold to a Buy and the price target has been revised to $12. Analysts at Maxim Group downgraded the stock from ‘”a Buy”‘ to ‘”a Hold”‘ outlook in a report released in mid November. As of December 19, 2016, Maxim Group has reiterated its “Buy” rating for BCLI. Earlier on December 22, 2015, Maxim Group resumed its rating. Their recommendation was “a Buy” for BCLI stock.
Analyzing BCLI Stock Performance
During the last five days, there has been a surge of approximately 38.10%. Over the course of the year, Brainstorm Cell Therapeutics, Inc shares have dropped approximately -57.51%. Shares of the company reached a 52-week high of $11.8905 on 03/25/24 and a 52-week low of $1.0500 on 11/14/24. A 50-day SMA is recorded $2.1091, while a 200-day SMA reached $5.1810. Nevertheless, trading volume fell to 0.15 million shares from 0.15 million shares the previous day.
Support And Resistance Levels for Brainstorm Cell Therapeutics, Inc (BCLI)
According to the 24-hour chart, there is a support level at 1.6333, which, if violated, would cause prices to drop to 1.5267. In the upper region, resistance lies at 1.8333. The next price resistance is at 1.9267. RSI (Relative Strength Index) is 54.23 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.2998, which suggests the price will decrease in the coming days. Percent R is at 10.39%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.
